Germline Testing for Predisposition to Myeloid Malignancies

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Christopher Reilly
Study ID
NCT07112287
Status
Recruiting
Apply to this trial

Conditions

  • Genetic Predisposition to Disease
  • Myeloid Hematological Malignancies
  • Myeloid Malignancy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • MyeloGen Gene Panel — DEVICE
    The MyeloGen Gene Panel is investigational Germline genetic testing using skin fibroblasts.

Study Details

The goal of this research study is to evaluate the feasibility of germline genetic testing using the investigational MyeloGen Gene Panel in adult participants diagnosed with myeloid malignancies.

Key Dates

Start date
Nov 10, 2025
Status verified
Apr 2026
Primary completion
Apr 1, 2030
Completion
Apr 1, 2033

Study Design

Enrollment
200 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING

Arms

  • Experimental: MyeloGen Germline Testing Group
    Enrolled participants will complete: * Baseline visit with questionnaires, educational video, and punch skin biopsy * Negative genetic test results notification via mail * Positive genetic results will be followed up by an appointment with a genetic counselor or physician * Post-results questionnaires * Follow up via medical records for up to 2 years from time of study consent.

Primary Outcome Measure

Successful Completion Rate [ Time Frame: Up to 10 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Dana-Farber Cancer InstituteBostonMassachusetts02215
Christopher R Reilly, MD
[email protected]
407-443-6243
Christopher R Reilly, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By research site
Dana-Farber Cancer Institute· Boston, MA

Related Studies